We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
+121.53%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
–
Cap. Flow
+$119M
Cap. Flow %
79.48%
Top 10 Hldgs %
69.97%
Holding
29
New
29
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$14.3M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$9.69M
3
ANAB icon
AnaptysBio
ANAB
+$8.52M
4
PTCT icon
PTC Therapeutics
PTCT
+$8.32M
5
KIDS icon
OrthoPediatrics
KIDS
+$7.19M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$23.8M 15.92%
+965,519
New +$14.3M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.2M 9.5%
+1,651,471
New +$5.9M
ARQL
3
DELISTED
Arqule Inc
ARQL
$11.9M 7.96%
+595,018
New +$6.9M
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$11M 7.34%
+414,408
New +$9.69M
PTCT icon
5
PTC Therapeutics
PTCT
$6.52B
$9.4M 6.3%
+195,725
New +$8.32M
KIDS icon
6
OrthoPediatrics
KIDS
$493M
$8.72M 5.85%
+185,618
New +$7.19M
LITS
7
Lite Strategy Inc
LITS
$33.6M
$7.75M 5.19%
+156,250
New +$5.81M
ASND icon
8
Ascendis Pharma A/S
ASND
$17.1B
$6.09M 4.08%
+43,775
New +$4.86M
ANAB icon
9
AnaptysBio
ANAB
$1.72B
$5.85M 3.92%
+360,100
New +$8.52M
YMAB
10
DELISTED
Y-mAbs Therapeutics
YMAB
$5.84M 3.91%
+186,749
New +$5.53M
NEO icon
11
NeoGenomics
NEO
$1.9B
$5.8M 3.89%
+198,348
New +$4.72M
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$8.88B
$5.16M 3.46%
+205,726
New +$3.92M
TVRD
13
Tvardi Therapeutics
TVRD
$30M
$4.58M 3.07%
+7,894
New +$5.54M
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$4.54M 3.04%
+187,976
New +$3.89M
CTMX icon
15
CytomX Therapeutics
CTMX
$788M
$3.96M 2.65%
+476,110
New +$3.21M
DCPH
16
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.72M 2.5%
+59,818
New +$2.84M
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.67M 1.79%
+70,653
New +$2.63M
AUPH icon
18
Aurinia Pharmaceuticals
AUPH
$2.05B
$2.56M 1.72%
+126,533
New +$1.17M
USPH icon
19
US Physical Therapy
USPH
$1.12B
$2.46M 1.65%
+21,500
New +$2.68M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$2.3M 1.54%
+75,227
New +$2.08M
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.29M 1.54%
+104,047
New +$2.09M
ABMD
22
DELISTED
Abiomed Inc
ABMD
$1.73M 1.16%
+10,138
New +$1.88M
KRRO icon
23
Korro Bio
KRRO
$177M
$938K 0.63%
+1,070
New +$832K
WVE icon
24
Wave Life Sciences
WVE
$1.12B
$849K 0.57%
+105,986
New +$2.6M
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
$366K 0.25%
+3,180
New +$280K
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Burrage Capital Management, which disclosed 29 positions worth $149M. Its ten largest holdings account for 70% of the portfolio.

Its largest position is Epizyme, Inc: 965,519 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets.

  • Burrage Capital Management's largest Q4 2019 buy was Epizyme, Inc: 965,519 shares worth $23.8M.
  • Burrage Capital Management's ten largest holdings make up 70% of its $149M portfolio in Q4 2019.
  • Burrage Capital Management disclosed 29 positions in Q4 2019, its first 13F filing on record.

Based on Burrage Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.